From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis
How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychos...
Gespeichert in:
Veröffentlicht in: | Schizophrenia research 2005-11, Vol.79 (1), p.59-68 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 68 |
---|---|
container_issue | 1 |
container_start_page | 59 |
container_title | Schizophrenia research |
container_volume | 79 |
creator | Kapur, Shitij Mizrahi, Romina Li, Ming |
description | How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychosis. Focussing on dopamine's role in reward prediction and motivational salience we propose that psychosis arises from an aberrant assignment of novelty and salience to objects and associations. Antipsychotics block dopamine receptors and decrease dopamine transmission, which leads to the attenuation of aberrant novelty and salience. This ‘salience’ framework accounts for existing data and questions several current assumptions about the speed of onset phenomenological effects of antipsychotics and their behavioral effects in animal models. We review new data to show that in contrast to the prevailing idea of a “delayed onset” of antipsychotic action, the improvement is evident in the first few days. Antipsychotics do not eradicate symptoms, but create a state of “detachment” from them. And the actions of antipsychotics in the conditioned avoidance response model, one of the best established animal models for identifying antipsychotic action, are consistent with the idea that they dampen aberrant as well as normal motivational salience. The article discusses the caveats, limitations as well as the clinical implications of the salience framework. |
doi_str_mv | 10.1016/j.schres.2005.01.003 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68651372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S092099640500037X</els_id><sourcerecordid>68651372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-c99fce44e9ddbfe8fcba2cf1bfa696d10aea4b0542f321da760585eeb935a6e73</originalsourceid><addsrcrecordid>eNp9kMFu1DAQhq2qiC6FN6hQLuVEwjiJnfWlElpRQKrEBc7WxB53vSRxau8i7Y2H4Al5EtzdlfbGwbJn9P0z1sfYDYeKA5cfNlUy60ipqgFEBbwCaC7YgouuKWsB6pItQNVQKiXbK_YqpQ0AcAHdS3bFZc5wxReM7mMYCxtmHP1ExTYUCQdPkzm857Q365B8-vv7z-Cnn356LHofhvC4f1_Ma4wjmkNV4GRzg6Yw5nPoBHeOv2YvHA6J3pzua_bj_tP31Zfy4dvnr6uPD6VphdyWRilnqG1JWds7WjrTY20c7x1KJS0HJGx7EG3tmppb7CSIpSDqVSNQUtdcs3fHuXMMTztKWz36ZGgYcKKwS1oupeBNV2ewPYImhpQiOT1HP2Lcaw76Wa_e6KNe_axXA9dZb469Pc3f9SPZc-jkMwO3JwCTwcFFnIxPZ67jSkopMnd35Cjb-OUp5m0H69ZHMlttg___T_4BRreexQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68651372</pqid></control><display><type>article</type><title>From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kapur, Shitij ; Mizrahi, Romina ; Li, Ming</creator><creatorcontrib>Kapur, Shitij ; Mizrahi, Romina ; Li, Ming</creatorcontrib><description>How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychosis. Focussing on dopamine's role in reward prediction and motivational salience we propose that psychosis arises from an aberrant assignment of novelty and salience to objects and associations. Antipsychotics block dopamine receptors and decrease dopamine transmission, which leads to the attenuation of aberrant novelty and salience. This ‘salience’ framework accounts for existing data and questions several current assumptions about the speed of onset phenomenological effects of antipsychotics and their behavioral effects in animal models. We review new data to show that in contrast to the prevailing idea of a “delayed onset” of antipsychotic action, the improvement is evident in the first few days. Antipsychotics do not eradicate symptoms, but create a state of “detachment” from them. And the actions of antipsychotics in the conditioned avoidance response model, one of the best established animal models for identifying antipsychotic action, are consistent with the idea that they dampen aberrant as well as normal motivational salience. The article discusses the caveats, limitations as well as the clinical implications of the salience framework.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/j.schres.2005.01.003</identifier><identifier>PMID: 16005191</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult and adolescent clinical studies ; Antipsychotic Agents - pharmacology ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Biological and medical sciences ; Chlorpromazine - pharmacology ; Chlorpromazine - therapeutic use ; Dopamine ; Dopamine - metabolism ; Humans ; Medical sciences ; Motivation ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Psychosis ; Psychotic Disorders - drug therapy ; Psychotic Disorders - epidemiology ; Receptors, Dopamine D2 - drug effects ; Salience ; Schizophrenia</subject><ispartof>Schizophrenia research, 2005-11, Vol.79 (1), p.59-68</ispartof><rights>2005 Elsevier B.V.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-c99fce44e9ddbfe8fcba2cf1bfa696d10aea4b0542f321da760585eeb935a6e73</citedby><cites>FETCH-LOGICAL-c456t-c99fce44e9ddbfe8fcba2cf1bfa696d10aea4b0542f321da760585eeb935a6e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S092099640500037X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17196665$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16005191$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kapur, Shitij</creatorcontrib><creatorcontrib>Mizrahi, Romina</creatorcontrib><creatorcontrib>Li, Ming</creatorcontrib><title>From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychosis. Focussing on dopamine's role in reward prediction and motivational salience we propose that psychosis arises from an aberrant assignment of novelty and salience to objects and associations. Antipsychotics block dopamine receptors and decrease dopamine transmission, which leads to the attenuation of aberrant novelty and salience. This ‘salience’ framework accounts for existing data and questions several current assumptions about the speed of onset phenomenological effects of antipsychotics and their behavioral effects in animal models. We review new data to show that in contrast to the prevailing idea of a “delayed onset” of antipsychotic action, the improvement is evident in the first few days. Antipsychotics do not eradicate symptoms, but create a state of “detachment” from them. And the actions of antipsychotics in the conditioned avoidance response model, one of the best established animal models for identifying antipsychotic action, are consistent with the idea that they dampen aberrant as well as normal motivational salience. The article discusses the caveats, limitations as well as the clinical implications of the salience framework.</description><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Biological and medical sciences</subject><subject>Chlorpromazine - pharmacology</subject><subject>Chlorpromazine - therapeutic use</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Motivation</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Psychosis</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Psychotic Disorders - epidemiology</subject><subject>Receptors, Dopamine D2 - drug effects</subject><subject>Salience</subject><subject>Schizophrenia</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFu1DAQhq2qiC6FN6hQLuVEwjiJnfWlElpRQKrEBc7WxB53vSRxau8i7Y2H4Al5EtzdlfbGwbJn9P0z1sfYDYeKA5cfNlUy60ipqgFEBbwCaC7YgouuKWsB6pItQNVQKiXbK_YqpQ0AcAHdS3bFZc5wxReM7mMYCxtmHP1ExTYUCQdPkzm857Q365B8-vv7z-Cnn356LHofhvC4f1_Ma4wjmkNV4GRzg6Yw5nPoBHeOv2YvHA6J3pzua_bj_tP31Zfy4dvnr6uPD6VphdyWRilnqG1JWds7WjrTY20c7x1KJS0HJGx7EG3tmppb7CSIpSDqVSNQUtdcs3fHuXMMTztKWz36ZGgYcKKwS1oupeBNV2ewPYImhpQiOT1HP2Lcaw76Wa_e6KNe_axXA9dZb469Pc3f9SPZc-jkMwO3JwCTwcFFnIxPZ67jSkopMnd35Cjb-OUp5m0H69ZHMlttg___T_4BRreexQ</recordid><startdate>20051101</startdate><enddate>20051101</enddate><creator>Kapur, Shitij</creator><creator>Mizrahi, Romina</creator><creator>Li, Ming</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051101</creationdate><title>From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis</title><author>Kapur, Shitij ; Mizrahi, Romina ; Li, Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-c99fce44e9ddbfe8fcba2cf1bfa696d10aea4b0542f321da760585eeb935a6e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Biological and medical sciences</topic><topic>Chlorpromazine - pharmacology</topic><topic>Chlorpromazine - therapeutic use</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Motivation</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Psychosis</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Psychotic Disorders - epidemiology</topic><topic>Receptors, Dopamine D2 - drug effects</topic><topic>Salience</topic><topic>Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kapur, Shitij</creatorcontrib><creatorcontrib>Mizrahi, Romina</creatorcontrib><creatorcontrib>Li, Ming</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kapur, Shitij</au><au>Mizrahi, Romina</au><au>Li, Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>2005-11-01</date><risdate>2005</risdate><volume>79</volume><issue>1</issue><spage>59</spage><epage>68</epage><pages>59-68</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychosis. Focussing on dopamine's role in reward prediction and motivational salience we propose that psychosis arises from an aberrant assignment of novelty and salience to objects and associations. Antipsychotics block dopamine receptors and decrease dopamine transmission, which leads to the attenuation of aberrant novelty and salience. This ‘salience’ framework accounts for existing data and questions several current assumptions about the speed of onset phenomenological effects of antipsychotics and their behavioral effects in animal models. We review new data to show that in contrast to the prevailing idea of a “delayed onset” of antipsychotic action, the improvement is evident in the first few days. Antipsychotics do not eradicate symptoms, but create a state of “detachment” from them. And the actions of antipsychotics in the conditioned avoidance response model, one of the best established animal models for identifying antipsychotic action, are consistent with the idea that they dampen aberrant as well as normal motivational salience. The article discusses the caveats, limitations as well as the clinical implications of the salience framework.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>16005191</pmid><doi>10.1016/j.schres.2005.01.003</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0920-9964 |
ispartof | Schizophrenia research, 2005-11, Vol.79 (1), p.59-68 |
issn | 0920-9964 1573-2509 |
language | eng |
recordid | cdi_proquest_miscellaneous_68651372 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Adult and adolescent clinical studies Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Antipsychotics Biological and medical sciences Chlorpromazine - pharmacology Chlorpromazine - therapeutic use Dopamine Dopamine - metabolism Humans Medical sciences Motivation Neuropharmacology Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Psychosis Psychotic Disorders - drug therapy Psychotic Disorders - epidemiology Receptors, Dopamine D2 - drug effects Salience Schizophrenia |
title | From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A28%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20dopamine%20to%20salience%20to%20psychosis%E2%80%94linking%20biology,%20pharmacology%20and%20phenomenology%20of%20psychosis&rft.jtitle=Schizophrenia%20research&rft.au=Kapur,%20Shitij&rft.date=2005-11-01&rft.volume=79&rft.issue=1&rft.spage=59&rft.epage=68&rft.pages=59-68&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/j.schres.2005.01.003&rft_dat=%3Cproquest_cross%3E68651372%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68651372&rft_id=info:pmid/16005191&rft_els_id=S092099640500037X&rfr_iscdi=true |